The Joslin Guideline for Detection and Management of Diabetes in Pregnancy is designed to assist internal medicine specialists, endocrinologists and obstetricians in individualizing the care of and setting goals for women with pre-existing diabetes who are pregnant or planning pregnancy. It is also a guide for managing women who are at risk for or who develop Gestational Diabetes Mellitus (GDM). This Guideline is not intended to replace sound medical judgment or clinical decision-making. Clinical judgment determines the need for adaptation in all patient care situations; more or less stringent interventions may be necessary.

The objectives of the Joslin Guideline for Detection and Management of Diabetes in Pregnancy are to support clinical practice and to influence clinical behaviors in order to improve clinical outcomes and assure that patient expectations are reasonable and informed. Guidelines are developed and approved through the Clinical Oversight Committee that reports to the Chief Medical Officer of the Joslin Diabetes Center. The Guideline is established after careful review of current evidence, medical literature and sound clinical practice. This Guideline will be reviewed periodically and modified as clinical practice evolves and medical evidence suggests.

### SCREENING FOR GESTATIONAL DIABETES MELLITUS

See Screening Strategy to Detect GDM on page 7.

#### PRECONCEPTION CARE

<table>
<thead>
<tr>
<th>Glucose Goals Prior to Conception</th>
<th>Pre-existing type 1 or type 2 diabetes</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Fasting and pre-meal blood glucose:</td>
<td>80-110 mg/dl</td>
</tr>
<tr>
<td>• 1 hour postprandial blood glucose:</td>
<td>100-155 mg/dl</td>
</tr>
<tr>
<td>• A1C:</td>
<td>&lt; 7% and as close to 6% as possible without resulting severe hypoglycemia</td>
</tr>
<tr>
<td>• Avoid severe hypoglycemia</td>
<td></td>
</tr>
</tbody>
</table>

**Counseling**

- Educate women of childbearing age about the importance of near normal blood glucose control prior to conception
- Refer to a maternal fetal-medicine and/or endocrinologist/diabetes specialist for counseling, assessment of maternal and fetal risk and guidance in achieving management goals. This includes all women who are planning pregnancy and women who are not planning pregnancy but are using inadequate contraception and have a glycosylated hemoglobin A1C greater than 7%.
- Assess diabetes self-management, including meal plan, insulin care and use, activity program, medication schedule, self-monitoring of blood glucose (SMBG), treatment for hypo and hyperglycemia, and sick day management, utilizing diabetes educators (DE) as appropriate. Review maternal and fetal health issues.
- Begin a multivitamin with 400 mcg of folic acid to supplement average daily intake of 400 mcg for a total daily intake of 800 mcg to 1 mg of folic acid to decrease the risk of neural tube defects. Patients with a prior pregnancy affected with a neural tube defect should take folic acid 4 mgs daily.
- Strongly advise smoking and alcohol cessation
- Refer overweight and obese women with and without known diabetes or polycystic ovary syndrome (PCOS) for medical nutrition therapy with a goal of 5-10% weight loss based on Institute of Medicine (IOM) 2009 recommendation.

**Medical Assessment**

- Medical and obstetrical history: including comprehensive review of diabetes history and management
- Eye evaluation: dilated comprehensive eye exam and pregnancy clearance by an ophthalmologist; should also include a discussion about the risk of developing and/or the progression of diabetic retinopathy during pregnancy
- Kidney function assessment: random urine albumin/creatinine ratio and serum creatinine. Refer to nephrology if urine protein ≥1 gram.
- Thyroid evaluation: TSH level
- GYN evaluation: pelvic exam, Pap smear up to date
- Cardiac evaluation: if asymptomatic, ≥ 35 years of age with one or more additional risk factors (hypertension, smoking, family history of CAD, hypercholesterolemia, albuminuria or nephropathy) recommend one or more of the following: EKG, echocardiogram or exercise tolerance test (ETT). If symptomatic, recommend EKG and echocardiogram or ETT and consider referral to cardiologist.
- Check a B12 level in patients consuming more than 1 mg folic acid, as high dose folic acid may mask B12 deficiency
**Diabetes Medications**

- Discontinue oral antihyperglycemic therapy; start insulin. An exception is metformin, which may be continued during the first trimester in patients with PCOS or type 2 diabetes, and anovulatory infertility. At the first prenatal visit, the patient should begin increasing doses of insulin as necessary to control blood glucose while metformin is tapered off or discontinued. Metformin should not be used beyond the first trimester or in lieu of insulin until randomized controlled studies evaluating safety and efficacy have been completed.
  - Metformin crosses the placenta and achieves therapeutic levels in the fetus. Presently, there are no long term randomized controlled safety data in infants whose mother’s were treated with metformin in pregnancy.
  - Other oral medications have not been adequately studied for the treatment of preexisting type 2 diabetes in pregnancy.
- The rapid-acting insulin analogs lispro and aspart lower postprandial blood glucose and decrease the risk of nocturnal hypoglycemia. Patients on lispro and aspart prior to conception may continue them during pregnancy. Patients on regular insulin may be switched to lispro or aspart if 1-hour postprandial blood glucose levels are above target and/or the patient is also experiencing pre-meal or nocturnal hypoglycemia.
- There is no information on the safety of using the insulin analogs, glulisine and degludec in pregnancy. We cannot recommend their use at this time.
- The rapid-acting insulins, lispro or aspart may be delivered either through multiple daily injections (MDI) or an insulin pump.
- Detemir is a long-acting insulin analog that has been studied in type 1 diabetes and is non-inferior to NPH insulin in terms of safety and efficacy and outcomes.
- Glargine, a long-acting insulin analog, is not recommended in women who are planning a pregnancy or who are currently pregnant. There is no information on its safety in pregnancy. A specific concern in the pregnant population is related to the 6 to 8 fold increased IGF-1 receptor affinity and mitogenic potency compared with human insulin.
- There is inadequate safety information about the use of GLP-1 agonists, DPP-4 inhibitors, alpha-glucosidase inhibitors, and SGLT2 inhibitors in pregnancy. They should therefore not be used in pregnancy.

**Other Medications**

**Hypertension and/or albuminuria management:**
- ACE-inhibitors and ARBs should be stopped pre-conception due to the increased risk of fetal injury or demise with 2nd or 3rd trimester use. Data on teratogenicity of ACE-inhibitors and ARBs is inconsistent therefore risks and benefits of continuing them should be weighed.
  - The non-dihydropyridine calcium channel blocker diltiazem in extended release forms may be a useful substitute for ACE-inhibitors and ARBs.
  - Switch to antihypertensive agents that are safe in pregnancy (see below).

**Diabetic nephropathy/chronic renal disease management:**
- The benefits of preconception use of ACE-inhibitors for renal protection may outweigh the uncertain risk of birth defects. In this case, ACE-inhibitors should be stopped as soon as pregnancy is diagnosed in the first trimester.

**Hyperlipidemia management:**
- Stop all cholesterol-lowering agents before conception, including statins
- Hypertriglyceridemia: omega 3 fatty acids may be started or continued in pregnancy

**DIABETES MANAGEMENT DURING PREGNANCY**

**Self Monitoring of Blood Glucose and Urine Ketones**

**Pre-existing diabetes and GDM**
- For gestational diabetes, check glucose levels 4 times/day: before breakfast and 1 hour post-meals
- For pre-existing diabetes, check glucose levels pre-meals and 1 hour post-meal
- Nocturnal monitoring (~3 AM) may be necessary on an intermittent basis
- Check fasting urine ketones daily

**Treatment Goals**

**Pre-existing Diabetes**
- Fasting and pre-meal plasma glucose 60-99 mg/dl
- 1-hour post-meal or peak post-prandial plasma glucose 100-129 mg/dl
- Urine ketones: negative
- Normalization of glycohemoglobin A1C to < 6% if possible without resulting severe hypoglycemia
- Use standard glycohemoglobin treatment for blood glucose less than 60 mg/dl (15 grams of carbohydrate – recheck in 15 minutes; repeat with 15 grams of carbohydrate if blood glucose is still less than 60 mg/dl)
- Avoidance of severe hypoglycemia (episode in which patient experiences coma, seizure or suspected seizure, or impairment sufficient to require the assistance of another person). Blood glucose goals must be relaxed for patients with hypoglycemia unawareness or recurrent hypoglycemia.

---

Copyright © 2016 by Joslin Diabetes Center, Inc. All rights reserved. Any reproduction of this document, which omits Joslin’s name or copyright notice is prohibited. This document may be reproduced for personal use only. It may not be distributed or sold. It may not be published in any other format without the prior, written permission of Joslin Diabetes Center, Publications Department, 617-226-5815.
### Gestational Diabetes

| Plasma glucose Hadlock AC < 75th percentile | 60-95 mg/dl |
| Plasma glucose Hadlock AC > 75th percentile | 60-79 mg/dl |

- **Fasting and premeal blood glucose**
- **1-hour post meal or peak post prandial**
- **Urine ketones**: negative
- **Initiate insulin therapy if above levels are not maintained**
- Use standard hypoglycemia treatment for blood glucose less than 60 mg/dl (15 grams of carbohydrate - recheck in 15 minutes; repeat with 15 grams of carbohydrate if blood glucose is still less than 60 mg/dl)

### Pre-existing Diabetes

- Medical visits (endocrinologist preferred) every 1-4 weeks, with additional phone contact as needed, depending on level of self-management skills and stability of blood glucose control. At each visit, review SMBG and urine ketone results, measure blood pressure, measure urine protein and ketones by dipstick.
- Check A1C level every 4-8 weeks
- Education utilizing a diabetes educator (DE), preferably a Certified Diabetes Educator (CDE), as needed; nutrition therapy (NT) by registered dietitian (RD)
- Ophthalmology exam early in first trimester; with repeat dilated exam every trimester and for 1 year postpartum as indicated by the degree of retinopathy
- Consider providing mental health counseling to assist women and / or their partners cope with the psychological and relationship changes that may result from pregnancy.

### Gestational Diabetes

- Medical visits (endocrinologist preferred) every 1-4 weeks, with additional phone contact as needed, depending on level of self-management skills and stability of blood glucose control. At each visit, review SMBG and urine ketone results, measure blood pressure, measure urine protein and ketones by dipstick.
- If newly diagnosed with gestational diabetes, patient should be started on insulin, not metformin or glyburide (glibenclamide), if medication is required.
- Education utilizing a DE (preferably a CDE) as needed for review of SMBG to increase adherence; NT by registered dietitian (RD)
- Glyburide is associated with a 2 fold or greater increased risk of macrosomia and neonatal hypoglycemia compared with insulin, in a meta-analysis.
- Glyburide should not be used in pregnancy, except in rare situations when insulin is not an option.
- Metformin is associated with high treatment failure rates, increased preterm delivery although lower neonatal hypoglycemia. **Long term safety data is not available. If insulin is not an option, metformin is preferred over glyburide**

### Diabetes Medications

- The only diabetes medication currently used throughout pregnancy is insulin (see [Preconception Care](#)).

### Hypertension Management

- Maintaining blood pressure in non-pregnant patients at < 130/80mmHg decreases end organ damage.
- Target blood pressure is 110-129 systolic and 65-79 diastolic in women with chronic hypertension during pregnancy. Antihypertensives are initiated in pregnant patients with known or suspected chronic hypertension if blood pressure is ≥ 130/80mmHg three times during pregnancy.
- Pre-eclampsia needs special treatment; therefore, these guidelines and treatment strategies do not apply to pre-eclampsia for which other treatment options are preferred, or to gestational hypertension when high blood pressure exposure is limited
- Antihypertensives that are used during pregnancy are:
  - Alpha methyldopa (category B)
  - Beta-blockers:
    - acebutolol, sotalol are category B
    - betaxolol, bisoprolol, labetalol, levatol, metoprolol, nadolol, timolol are category C
    - atenolol is category D and should not be used as it may cause fetal growth restriction
  - Calcium channel blockers are all category C. The nondihydropyridine calcium channel blocker diltiazem in extended-release form may be preferred in patients with microalbuminuria or nephropathy.
  - Hydralazine is category C
- Aspirin 81 mg daily is recommended from 12-36 weeks to help reduce risk for preeclampsia in patients with type 1 or 2 diabetes.
NUTRITION THERAPY (NT) AND DIABETES SELF-MANAGEMENT EDUCATION (DSME)

Recommendations are the same for pre-existing diabetes and GDM except where noted.

Counseling and Education

- All pregnant women should receive NT counseling by a registered dietitian (RD), (CDE preferred)
- All pregnant women should receive SMBG training by a DE (CDE preferred)
- Daily food records and SMBG records are required to assess effectiveness of NT
- Carbohydrate counting skills are taught for either a consistent carb intake or a personalized insulin to carb ratio so the patient can adjust insulin based on carbohydrate intake
- At least 3 encounters with a CDE are recommended:
  - Visit 1 (60 – 90 minute individual or group visit with RD) for assessment and meal planning. This could include SMBG instruction if RD has received appropriate training.
  - Visit 2 (30 – 45 minute) with RD or RN 1 week after initial visit to assess and modify plan
  - Visit 3 (15 – 45 minute) with RD or RN in 1 – 3 weeks to further assess and modify plan, as needed.
- Additional visits every 2 – 3 weeks and prn with RD or RN until delivery, and one visit 6 – 8 weeks after delivery

Calories

<table>
<thead>
<tr>
<th>WHO BMI range (kg/m²)</th>
<th>Energy Needs (kcal/kg) Based on Pregravid kg</th>
<th>Total Weight Gain Range (lbs)</th>
<th>Rates of weight Gain (lb/week) 2nd and 3rd trimesters</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Single</td>
<td>Multiple</td>
<td>Single</td>
</tr>
<tr>
<td>Underweight: &lt;18.5</td>
<td>36-40</td>
<td>42-50</td>
<td>28-40</td>
</tr>
<tr>
<td>Normal weight: 18.5-24.9</td>
<td>30</td>
<td>40-45</td>
<td>25-35</td>
</tr>
<tr>
<td>Overweight: 25-29</td>
<td>24</td>
<td>30-35</td>
<td>15-25</td>
</tr>
<tr>
<td>Obese: &gt;=30</td>
<td>Insufficient information**</td>
<td>11-20</td>
<td>25-42</td>
</tr>
</tbody>
</table>

*Quick Guide to Calculate Energy Needs:

Estimated Energy Requirement’s (EER) for Pregnancy

EER pregnancy = EER pre-pregnancy + additional energy expended during pregnancy + energy deposition where:

First trimester = EER pre-pregnancy + 0
Second trimester = EER pre-pregnancy + 340 singleton
Third trimester = EER pre-pregnancy + 452 singleton

For 19yrs of age and older: EER pre-pregnancy = 354 – (6.91 X age (Y) + PA X (9.36 X weight (kg) + 726 X height (m)) where PA is the physical activity coefficient:

PA = 1.0 for sedentary (Physical Activity Level, PAL >/= 1.0 < 1.4)
PA = 1.12 for low active (PAL >/= 1.4 < 1.6)
PA = 1.27 for active (PAL >/= 1.6 < 1.9)
PA = 1.45 for very active (PAL >/= 1.9 < 2.5)

For twins pregnancy, add an additional 500 kcals to calculated needs after 1st trimester. For multiple pregnancies, add 500 kcal in the 1st trimester

* Insufficient information was available to develop a provisional guideline for underweight women with multiple fetuses
** Insufficient information to address energy needs (kcal/kg) in the obese category

Distribution of Calories

- Individualize distribution of calories based on usual intake, preferences and medication regimen.
  - Consistent timing of 3 meals and 2-4 snacks daily. Smaller frequent meals decrease postprandial hyperglycemia
  - Weight should be monitored at each visit; track patient’s weight gain on prenatal weight gain chart

Carbohydrate

<table>
<thead>
<tr>
<th>GDM</th>
<th>Pre-Existing Diabetes</th>
</tr>
</thead>
<tbody>
<tr>
<td>40 - 55% total calories'</td>
<td>40 - 55% total calories</td>
</tr>
<tr>
<td>Breakfast: 15 – 30 grams +</td>
<td>Consistent carb intake or individualized as per usual intake and BG levels</td>
</tr>
</tbody>
</table>
### Carbohydrates (continued)

<table>
<thead>
<tr>
<th>Other meals</th>
<th>45 grams lunch and dinner</th>
<th>Consistent carb intake or individualized as per usual intake and BG levels</th>
</tr>
</thead>
<tbody>
<tr>
<td>HS snack</td>
<td>15 - 30 grams carbohydrate</td>
<td>15 - 30 grams carbohydrate</td>
</tr>
</tbody>
</table>

Pregnant women should consume a minimum of 175 grams of carbohydrate per day
+ May be increased if insulin is added
Diet mainly containing low glycemic index carbohydrates
Carbohydrate counting at each meal and snack

### Fiber
- Calculate 14 grams of fiber per 1000 kcals per day (25-30 grams/day) based on provider assessment

### Protein
- Calculate 1.1 grams of protein per kg per day, based on provider assessment
- Multiple pregnancies: An additional 50 gram of protein per day, above the non-pregnant DRI for protein during 2nd and 3rd trimester

### Fat
- Pre-existing diabetes: 30 - 40% of total calories, with <10% total calories from saturated fat
- GDM: 30-40% total calories with <10% total calories from saturated fat
- Encourage use of monounsaturated and polyunsaturated fats instead of saturated fats (e.g., olive oil, canola oil, soybean oil, nuts/seeds, avocado and fish, particularly those high in omega-3 fatty acids) instead of saturated fats.
- Limit fish low in mercury to 12 ounces per week. (e.g. salmon, herring, trout, sardines as a source of omega-3 fatty acids). Avoid high mercury fish such as shark, swordfish, king mackerel, tile fish.

### Nutritive and Non-nutritive Sweeteners
- The safety of non-nutritive sweeteners has not been established.

### Vitamin/Mineral Supplement
- Prenatal multivitamin and mineral supplement including:
  - Iron (30 mg/day)
  - Folic acid 400 mcg to supplement average daily dietary intake of 400 mcg for a total daily intake of 800 mcg to 1 mg daily to decrease risk of neural tube defects (begin 400 mcg prior to conception)
  - Additional calcium supplementation may be needed to meet daily requirement of 1000 mg per day (1300 mg per day if under age 19yrs). Begin prior to conception.
  - Vitamin D 600 IUs/day.
    - Tolerable Upper Intake (UL): 4,000 IU/day for 12 weeks

### Caffeine/Fluid intake
- Limit caffeine to <200 mg per day (equivalent to 1 cup). Excess caffeine consumption during pregnancy may increase the risk of miscarriage
- 3 liters of water per day for adequate hydration or about 10 cups a day in total beverage intake

### Physical Activity
- Regular physical activity is recommended after clearance by provider. Engage in 30 minutes of moderate exercise on most days of the week or at least 150 minutes of moderate physical activity per week. Unless contraindications are present, previously inactive and active women should be encouraged to be physically active
  - Benefits include reducing insulin resistance, postprandial hyperglycemia and excessive weight gain
  - Hypoglycemia is more likely with prolonged exercise (>60 minutes)
  - Encourage activity after meals to reduce postprandial hyperglycemia

### Alcohol and Tobacco Use
- Alcohol and tobacco use should be avoided during pregnancy.
POST-PARTUM CARE

- Breastfeeding is encouraged in patients with pre-existing or gestational diabetes
- Enalapril and captopril may be used to treat hypertension and albuminuria in nursing mothers of full-term infants
- Appointments with the following specialists should be completed 6-8 weeks post-partum: ophthalmology, RD or RN and endocrinology.
- For women who develop GDM:
  - A 2-hour 75 g OGTT should be checked at 6 weeks to evaluate for persistent diabetes
    - Normal: fasting glucose level <100mg/dl
    - Impaired fasting glucose: fasting glucose level 100-125mg/dl
    - Diabetes: fasting glucose level ≥126mg/dl
    - Normal glucose tolerance: 2 hour OGTT value <140 mg/dl
    - Impaired glucose tolerance: 2 hour OGTT value 140-199mg/dl
    - Diabetes: 2 hr OGTT value > 200mg/dl
  - Counsel women with GDM on the role of lifestyle management and weight loss to reduce the risk of future type 2 DM (of note: approximately 50% of women with GDM will develop overt type 2 diabetes in the next 7 to 10 years)
  - Review nutrition guidelines and establish exercise goals. For women with BMI greater than 25 (or BMI ≥23 in Asians) target a 5-7% weight loss from the preconception weight.
- Discuss family planning/contraceptive issues. Depo-provera and progestin-only oral contraceptives are less preferred in patients who have had gestational diabetes, as they can accelerate the development of type 2 diabetes. In patients with pre-existing diabetes, depo-provera may worsen glycemic control. The intrauterine device (IUD) is preferred in monogamous partnerships because it is a metabolically neutral and highly effective form of contraception.
- Assist women with gestational diabetes with the transfer of care back to the primary care physician for longer term diabetes screening (including yearly fasting glucose, 1 year post partum and every 3 years afterwards 75 gram 2hour OGTT), risk reduction and for lifestyle management.
Gestational Diabetes Mellitus
Screening Strategy to Detect GDM
Risk assessment should be done at first prenatal visit

**HIGH RISK**
- Obesity OR
- Previous History of GDM OR
- Impaired OGTT or IFG OR
- PCOS OR
- Glycosuria OR
- Previous baby with >9 lbs birth weight OR
- Strong family hx of Diabetes (1st degree relative) OR
- Previous adverse pregnancy outcomes

**UNIVERSAL SCREENING** (for all women in the first trimester)

Screen in first trimester with one of the following:
- Fasting glucose OR
- A1c OR
- 2 hr 75 gm OGTT

**Normal Screen**
- Fasting glucose: < 110mg/dl OR
- A1C < 5.9%

Treat as GDM

**Abnormal Screen**
- Fasting glucose: 110-125mg/dl OR
- A1C: 5.9-6.2%

Treat as pre-existing diabetes

For Normal Initial Screen, One Step Method:
- Re-screen at 24-28 wks with 2hr, 75 gram OGTT.
  Check fasting, 1 hour and 2 hour values

**Normal 2 hour 75 gram OGTT Screen**: 34
- Fasting plasma glucose: < 92mg/dl OR
- 1 hour plasma glucose: < 180mg/dl OR
- 2 hour plasma glucose: < 153mg/dl

Normal if all values are normal

**Abnormal 2 hour 75 gram OGTT Screen**: 34
- Fasting plasma glucose: ≥ 92mg/dl OR
- 1 hour plasma glucose: ≥ 180mg/dl OR
- 2 hour plasma glucose: ≥ 153mg/dl

Abnormal if one or more values are met or exceeded

For Normal Initial Screen, Two Step Method:
- Re-screen at 24-28 wks with 50 gram OGTT (nonfasting) with PG measurement at 1 hr (Step 1),

**Normal Two Step Method Screen**: 5.56
- PG at 1hr after load is < 140mg/dl

Normal if fewer than two values are met or exceeded

**Abnormal Two Step Method Screen**: 5.56
- If PG at 1hr after load is ≥140mg/dl, proceed to 100gram OGTT (Step 2), performed while patient is fasting

**Abnormal 100 gram OGTT Screen**: 5.56
- Fasting plasma glucose: > 95mg/dl OR
- 1 hour plasma glucose: > 180mg/dl OR
- 2 hour plasma glucose: > 155 mg/dl OR
- 3 hour plasma glucose: > 140mg/dl

Abnormal if two or more values are met or exceeded

**Normal 100 gram OGTT Screen**: 5.56
- Fasting plasma glucose: < 95mg/dl OR
- 1 hour plasma glucose: < 180mg/dl OR
- 2 hour plasma glucose: < 155 mg/dl OR
- 3 hour plasma glucose: < 140mg/dl

Normal if fewer than two values are met or exceeded
Glossary

<table>
<thead>
<tr>
<th>Term</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>A1C</td>
<td>glycosylated hemoglobin</td>
</tr>
<tr>
<td>ACE</td>
<td>angiotensin converting enzyme inhibitor</td>
</tr>
<tr>
<td>Age (y)</td>
<td>age in years</td>
</tr>
<tr>
<td>ARB</td>
<td>angiotensin receptor blocker</td>
</tr>
<tr>
<td>BMI</td>
<td>body mass index</td>
</tr>
<tr>
<td>CAD</td>
<td>coronary artery disease</td>
</tr>
<tr>
<td>CDE</td>
<td>certified diabetes educator, a healthcare provider with advanced education in diabetes management</td>
</tr>
<tr>
<td>DE</td>
<td>diabetes educator</td>
</tr>
<tr>
<td>DPP-4 inhibitor</td>
<td>dipeptidyl-4 inhibitor</td>
</tr>
<tr>
<td>DRI</td>
<td>Dietary Reference Intake</td>
</tr>
<tr>
<td>EER</td>
<td>estimated energy requirement</td>
</tr>
<tr>
<td>EKG</td>
<td>electrocardiogram</td>
</tr>
<tr>
<td>ETT</td>
<td>exercise tolerance test</td>
</tr>
<tr>
<td>GDM</td>
<td>gestational diabetes mellitus</td>
</tr>
<tr>
<td>Hadlock AC</td>
<td>formula to identify macrosomia established by Hadlock et al</td>
</tr>
<tr>
<td>lb</td>
<td>pounds</td>
</tr>
<tr>
<td>IGF receptor</td>
<td>insulin-like growth factor receptor</td>
</tr>
<tr>
<td>IUD</td>
<td>intrauterine device</td>
</tr>
<tr>
<td>Kcals/kg</td>
<td>kilocalories per kilogram</td>
</tr>
<tr>
<td>Kg/m²</td>
<td>kilogram per meter</td>
</tr>
<tr>
<td>Mcg</td>
<td>microgram</td>
</tr>
<tr>
<td>MDA</td>
<td>multiple daily injection</td>
</tr>
<tr>
<td>mCG</td>
<td>microgram</td>
</tr>
<tr>
<td>mG</td>
<td>milligrams</td>
</tr>
<tr>
<td>mG/dL</td>
<td>milligrams per deciliter</td>
</tr>
<tr>
<td>mmol/L</td>
<td>millimoles per liter</td>
</tr>
<tr>
<td>NT</td>
<td>nutrition therapy</td>
</tr>
<tr>
<td>OGGT</td>
<td>oral glucose tolerance test</td>
</tr>
<tr>
<td>PA</td>
<td>physical activity co-efficient</td>
</tr>
<tr>
<td>PAL</td>
<td>physical activity level</td>
</tr>
<tr>
<td>PCOS</td>
<td>polycystic ovarian syndrome</td>
</tr>
<tr>
<td>PG</td>
<td>plasma glucose</td>
</tr>
<tr>
<td>RD</td>
<td>registered dietitian</td>
</tr>
<tr>
<td>SGLT2 inhibitor</td>
<td>sodium-glucose cotransporter-2 inhibitor</td>
</tr>
<tr>
<td>SMBG</td>
<td>self monitoring of blood glucose</td>
</tr>
<tr>
<td>TSH</td>
<td>thyroid stimulating hormone</td>
</tr>
<tr>
<td>MNT</td>
<td>medical nutrition therapy</td>
</tr>
<tr>
<td>UL</td>
<td>upper limit</td>
</tr>
</tbody>
</table>


Joslin Clinical Oversight Committee

Om Ganda, MD -Chairperson Medha Munshri, MD
Richard Beaser, MD J o-Anne Rizzotto, MEd, RD, CDE
Elizabeth Blair, MSN, ANP-BC, CDE Sylvia Rosas, MD
Jerry Cavallerano, OD, PhD Susan Sjostrom, J D
William Hsu, MD William Sullivan, MD
Lori Laffel, MD, MPH John Zrebiec, LICSW, CDE
Melinda Maryniuk, MEd, RD, CDE Robert Gabbay, MD (ex officio)

References:
nutrition and lifestyle for a healthy pregnancy outcome, practice paper.

35. Schaefer-graf um, kjos sl, fauzan oh, bühling kj, siebert g, bührer c, ladendorf b, dudenhausen jw, vetter k.


39. duran a, s’aenz s, torrejón mj, et al. introduction of iadpsg criteria for the screening and diagnosis of gestational diabetes mellitus results in improved pregnancy outcomes at a lower cost in a large cohort of pregnant women: the st. carlos gestational diabetes study. diabetes care 2014;37: 2442-2450

40. ethridge jk jr, catalano pm, waters tp. perinatal outcomes associated with the diagnosis of gestational diabetes made by the international association of the diabetes and pregnancy study groups criteria. obstet gyne col 2014;124:571-578

41. march mi, modest am, ralston sj, hacker mr, gupta m, brown fm. the effect of adopting the iadpsg screening guidelines on the risk profile and outcomes of the gestational diabetes population. j matern fetal neonatal med. 2016 apr;29(7):1141-5.. e pub 2015 may 11.

42. roskjaer, a anderssen j, roney, h., damm, p., mathiesen, e. dietary advices on carbohydrate intake for pregnant women with type 1 diabetes. j of matern-fetal & neonatal med 2015; 28 (2): 229-233.

43. m. karamali, e. beihaghi, a.a. mohammadi, a. asemi. effects of high-dose vitamin d supplementation on metabolic status and pregnancy outcomes in pregnant women at risk for pre-eclampsia. journal of endocrine care 2015; 47: 867-872


45. hernandez, t.l., vanpelt, r.e., anderson, m.a., et al. higher-complex carbohydrate diet in gestational diabetes mellitus achieves glucose targets in 28 day pregnant women: maintenance of improved metabolic control. diabetes care 2014;37:1254-1262.

46. nutrition and lifestyle for a healthy pregnancy outcome, practice paper.

47. zhu ww, yang hx, wei ym, et al. evaluation of the value of fasting plasma glucose in the first prenatal visit to

48. nutrition and lifestyle for a healthy pregnancy outcome, practice paper.

49. balsells m, garcia-patterson a, sola i, et al. glibenclamide, metformin, and insulin for the treatment of gestational diabetes: a systematic review and meta-analysis. bmj. 2015 j an 21;350:h102.


51. molvi sn, mir s, rana vs, jabeen f, malik ar. role of antihypertensive therapy in mild to moderate pregnancy-induced hypertension: a prospective randomized study comparing labetalol with alpha methyl dopa. arch gynecol obstet. 2012 j un;285(6):1553-62

52. hsu wc, araneta mr, kanaya am, et al. bmi cut points to identify at-risk asian americans for type 2 diabetes screening. diabetes care. 2015 j an;38(1):150-8

53. mathiesen er, hod m, ivanisevic m, et al. maternal efficacy and safety outcomes in a randomized, controlled trial comparing insulin detemir with nph insulin in 310 pregnant women with type 1 diabetes. diabetes care 2012;35:2012-2017

54. hod m, mathiesen er, jovanović l, et al. a randomized trial comparing perinatal outcomes using insulin detemir or neutral protamine hagedorn in type 1 diabetes. j matern fetal neonatal med. 2014 j an;27(1):7-13

55. tenagel's n, werner u, the metabolic and mitogenic properties of basal insulin analogues. arch physiol biochem. 2013 feb; 119(1): 1-14


58. waters, thaddeus et al. for the hapo cooperative study research group, maternal and neonatal morbidity for women who would be added to the diagnosis of gdm using iadpsg criteria: a secondary analysis of the hyperglycemia and adverse pregnancy outcome study. diabetes care. 2016

59. retnakaran, r et al. fetal sex and maternal risk of gestational diabetes mellitus: the impact of having a boy. diabetes care 2015; 38: 844-851

60. johansson, k et al. outcomes of pregnancy after bariatric surgery. n engl j med 2015; 372: 814-824